We have established an excellent track record of in-licensing and out-licensing deals with our global and regional partners. These in-licensing deals enable us to acquire multiple novel or highly differentiated clinical-stage assets with favorable clinical safety and early efficacy data. We have quickly built our China Portfolio through in-licensing deals with global biotech partners, including MorphoSys, Genexine, MacroGenics and Ferring, and is the reason we are often regarded as a preferred China partner because of our strong development capabilities and proven track record. The out-licensing deals enable us to streamline our pipeline and focus our resources on the most valuable assets. In addition, we seek co-development opportunities to share development costs and risks, and territorial commercial rights, with our partners. 

In the past two years, we have out-licensed three assets and initiated four co-development programs with our partners ABL Bio, Everest Medicines and WuXi Biologics. The revenue from out-licensing and co-development deals is expected to continue to grow as our pipeline progresses.


Partnering Opportunities

At I-Mab, we strive to develop innovative therapies that have the potential to become novel or highly differentiated medicines.

Currently, we are seeking strategic partners in the following areas:

In-licensing highly differentiated large molecules in immuno-oncology and autoimmune diseases;
Co-development and co-commercialization of our innovative products for the global market.

BD Contacts:

If you are interested in exploring business opportunities with us, please send your request to: BD@i-mabbiopharma.com
Copyright I-MAB Biopharma Co., Ltd. All rights reserved 2019 沪ICP备17007960号-2